One Step Closer to an Ebola Virus Vaccine
Despite the slowing and eventual halting of the spread of Ebola virus disease (EVD) in West Af rica, 1,2 the battle for preventing and managing future outbreaks is still on. This is no time to be complacent. The scale of the outbreak, in which every few days during the early part of the out break about the same number of cases accrued as occurred during the entire 3month outbreak in Gulu, Uganda, in 2000-2001 -previously the largest outbreak on record -prompted us to pull out all the stops, albeit after a slow start. 3 Vaccines are a key weapon in our armamentarium against EVD. For some years, a number of prom ising vaccine candidates have been identified, with many more in development. The two lead ing candidates are vectored vaccines in which the Ebola virus glycoprotein is presented in a replicationincompetent chimpanzee adenovirus 3 (cAd3) or a replicationcompetent vesicular sto matitis virus (VSV). Both vaccines showed 100% protection in nonhuman primates at 4 to 5 weeks after single doses were administered and were rushed into phase 1 trials in hopes that the promise of a vaccine that could help stem an epidemic of EVD could be more than theoretical.
Ledgerwood and colleagues now present in the Journal the final results of the phase 1 VRC 207 trial, a nonrandomized, openlabel trial of two dose levels of a cAd3vectored bivalent vac cine against the two most virulent species of ebolavirus, Zaire and Sudan. 4 They conclude that the vaccine is without significant safety concerns and is immunogenic, inducing strong humoral and cellmediated responses. Although the re sults of the trial are indeed promising, questions remain; both immunogenicity and reactogenicity were dosedependent. The higher dose, which was required to generate the more vigorous im mune response, was also associated with sys temic symptoms in 70% of the participants, in cluding one in whom a high fever (temperature, 39.9°C) developed, and with transient leukopenia in 20%. There were no major adverse effects, but the sample size (10 persons at each dose level) is too small to draw firm conclusions in this re gard. Of particular concern is that the virus specific CD8 Tcell response, which may be a key correlate of protection, 5 was only 20% in the lowerdose group and 70% in the higherdose group. Getting the dose right has relevance not only for ensuring individual protection and mini mizing adverse effects, but also for stretching the vaccine supply to the maximum number of doses possible to combat the ongoing outbreak.
Interpretation of the findings of the study by Ledgerwood et al., as with all studies of filovirus vaccines, is hampered by a lack of knowledge regarding the specific correlates of immunity, although, as the authors point out, the immune responses observed in their study involving hu mans are consistent with those associated with protection in efficacy studies in nonhuman pri mates. 5 The matter is further complicated by a lack of standardization of stock viruses 6 and the fact that, to achieve 100% mortality in control animals -and thus interpretable results -in studies in nonhuman primates, an extremely high challenge dose of virus (1000 plaqueforming units) is used, which is probably orders of mag nitude higher than the inoculum that typically infects a human. Until the correlates of immu nity are better understood, it is impossible to say whether the immune response shown at the lower dose in the study by Ledgerwood et al., which caused fewer side effects, is "good enough." Will similar results be observed in West Africa, where malaria is holoendemic and has been as sociated with diminished immunogenicity with other vectored vaccines? 7 At exactly what time point after vaccination is adequate immunity conferred? This is an important question, given the urgency of this type of situation. Will it be necessary to administer a booster with a modi fied vaccinia Ankara (MVA) vaccine expressing the Ebola glycoprotein, which has been shown to increase the duration of immunity but would considerably complicate delivery? 8 Results from ongoing phase 1 trials of a monovalent cAd3 EBO Zaire vaccine, which may be more immuno genic than a bivalent formation, 9 as well as of the VSVvectored vaccine, in various locations in the United States, Europe, and Africa (outside 985 the epidemic area for EVD), are informing the answers to these important questions.
Perhaps one of the only silver linings of the EVD crisis that shook West Africa several years ago is that the event pushed therapeutics and vaccines for EVD, which had previously been rela tively stalled in development despite the promis ing results in nonhuman primates, into acceler ated production and clinical trials. Assuming that the findings of Ledgerwood et al. are con firmed, especially in African populations, cAd3 EBO certainly warrants efficacy trials, but there are difficult decisions regarding the best dose and the trial design. In the current report, the authors have updated their findings, presenting evidence of continued immune humoral and CD4 and CD8 cellular immune responses at 48 weeks after vaccination, although the peak re sponse was still at week 4. Whether the immune response at 48 weeks is still sufficient to confer protection is unknown, given the previously men tioned lack of specific correlates of immunity. The authors note subsequently published results of phase 1 and 2 studies of a monovalent cAd3 EBO vaccine, sometimes followed by an MVA boost, in which 1×10 11 particle units was deter mined to be the best dose on the basis of the immunogenicity and adverse event profile. Al though use of the monovalent cAd3EBO vaccine alone many be sufficient to confer shortterm immunity, which is of clear value for outbreak control, the use of adjuvants may be needed for longerterm protection. Phase 3 trials are planned, but important questions remain: can traditional phase 2 and 3 efficacy trials be performed in West Africa, given the many ethical considera tions; should the cAd3 and VSV vaccines be compared headtohead; what should the target population be; and can it all be arranged in a human trial, or will we ultimately need to turn to the Food and Drug Administration Animal Rule (which stipulates that under certain circum stances, the FDA may grant approval on the basis of wellcontrolled studies in animals)? 10 The road is still long and there are many challenges, but we are nevertheless one step closer to a solution.
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